Trial Profile
A Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Rozibafusp alfa (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Amgen
- 17 Mar 2021 Results of pharmacokinetic and PK/PD from phase I studies in healthy and RA subjects (NCT02618967, NCT03156023) presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 03 Jul 2020 Status changed from active, no longer recruiting to completed.
- 06 Jun 2020 Interim results (As of June 5, 2019; n= 34) presented at the 21st Annual Congress of the European League Against Rheumatism